中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

已收盘 12-05 16:09:08

6.840

-0.040

-0.58%

最高6.880	最低6.680	成交量4,889万
今开6.880	昨收6.880	日振幅2.91%
总市值1,283亿	流通市值1,283亿	总股本187.61亿
成交额3.33亿	换手率0.26%	流通股本187.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":6.84,"timestamp":1764922148003,"preClose":6.88,"halted":0,"volume":48888158,"delay":0,"floatShares":18761000000,"shares":18761000000,"eps":0.21065233997415297,"marketStatus":"已收盘","change":-0.04,"latestTime":"12-05 16:09:08","open":6.88,"high":6.88,"low":6.68,"amount":332783319,"amplitude":0.02907,"askPrice":6.84,"askSize":466000,"bidPrice":6.81,"bidSize":220000,"shortable":3,"etf":0,"ttmEps":0.23544086220104635,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":6.88,"dividendRate":0.013358,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":1.037096,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3794,"impliedVolPercentile":0.1748},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2588007417","title":"中国生物制药(01177)：TQF3250“口服偏向型GLP-1受体激动剂”临床试验申请获NMPA、FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588007417","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588007417?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:27","pubTimestamp":1764840424,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局和美国食品药品监督管理局的批准，拟用于减重。TQF3250是一款口服小分子偏向型GLP-1受体激动剂。与传统GLP-1药物相比，TQF3250通过选择性激活cAMP偏向的GLP-1受体信号通路，促进胰岛素分泌，同时减少β-arrestin募集和受体内吞，从而延长药效持续时间。除减重适应症外，TQF3250用于治疗2型糖尿病的临床试验申请已获NMPA批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLP","BK1589","BK1191","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","HK0000165453.HKD","BK4590","01177","BK1515","IE00BZ08YT58.USD","BK1521","BK4144"],"gpt_icon":0},{"id":"2588076380","title":"【券商聚焦】中泰国际：北京与上海相继出台政策支持创新医疗器械的开发 料有利于创新医疗器械板块发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2588076380","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588076380?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:04","pubTimestamp":1764810245,"startTime":"0","endTime":"0","summary":"医疗器械板块上涨，该机构估计是由于北京与上海相继出台政策支持创新医疗器械开发。北京出台《北京市促进医疗器械产业高质量发展若干措施》，提出多条举措支持创新器械的临床研发、注册上市、销售推广、产业链发展和出海。该机构认为以上政策有利于创新医疗器械板块的发展，但港股大型创新医疗器械生产商不多，该机构对传统医疗器械生产商的2025年业绩偏谨慎。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970861","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01066","LU0140636845.USD","159883","LU0819121731.USD","BK1191","LU2097828714.EUR","LU1969619763.USD","LU2242644610.SGD","LU0456827905.SGD","09997","01801","LU0051755006.USD","LU0359201612.USD","LU0456846285.SGD","LU0516423091.SGD","IE00BZ08YT58.USD","LU2097828631.EUR","LU2097828474.EUR","BK1574","BK1583","01177","LU0823426308.USD","LU0173614495.USD","LU2097828805.USD","LU3063872942.SGD","LU0856984785.SGD","LU2039709279.SGD","09996","LU0348825331.USD","LU0348735423.USD","HK0000165453.HKD","LU2488822045.USD","BK1100","02269","LU0516423174.USD","BK1141","LU2045819591.USD","LU0359202008.SGD","LU0708995583.HKD","LU1880383366.USD","LU0455707207.USD","02359","LU2125910500.SGD","BK1161","LU0823426480.USD","LU0307460666.USD","SG9999002463.SGD","03692","IE00B0JY6N72.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2589306028","title":"中美监管机构同时亮绿灯，中国生物制药TQF3250减重适应症临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2589306028","media":"正大制药订阅号","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589306028?lang=zh_cn&edition=full","pubTime":"2025-12-04 07:02","pubTimestamp":1764802926,"startTime":"0","endTime":"0","summary":"12月1日，中国生物制药1类新药TQF3250胶囊的临床试验申请获美国食品药品监督管理局批准，拟用于减重适应症。TQF3250具备独特的偏向型机制，除减重领域外，用于治疗2型糖尿病的临床试验申请已于近日正式获批。此外，TQF3250口服给药的方式相比于主流GLP-1药物的注射剂型，大幅提升了患者用药的便利性和长期治疗依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204070534a4cb30ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204070534a4cb30ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","BK1589","BK1515","BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","01177","HK0000165453.HKD","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2588173047","title":"港股公告掘金 | 英诺赛科与安森美半导体达成共同加速推进氮化镓产业生态建设的战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2588173047","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588173047?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:58","pubTimestamp":1764773894,"startTime":"0","endTime":"0","summary":"【重大事项】京东工业(07618)拟全球发售2.11亿股 预计12月11日上市中国燃气(00384)坚持“绿色城市运营商”战略方向构建多能互补的能源体系协同生态及与亿纬锂能订立战略合作协议中核国际(02302)间接控股母公司中国铀业正式登陆深交所 有力彰显其资本市场地位的提升英诺赛科(02577)与安森美半导体达成共同加速推进氮化镓产业生态建设的战略合作协议英诺赛科(02577)于与英飞凌的诉讼案","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU2357305700.SGD","BK1191","IE00BD6J9T35.USD","BK1521","00384","IE00BZ08YS42.EUR","BK1515","LU2360107325.USD","LU1720051017.SGD","BK4141","BK1566","BK1221","LU0640798160.USD","LU2298322129.HKD","BK4512","BK4588","LU1978683503.SGD","07618","LU1854103824.USD","02577","01177","LU0124384867.USD","LU0348723411.USD","LU1720051108.HKD","IE00BZ08YR35.GBP","LU1861214812.USD","IE00BZ199S13.USD","IE00BZ08YT58.USD","LU0724618433.USD","LU1548497426.USD","02302","HK0000165453.HKD","BK1124","LU1861219969.SGD","LU1861220033.SGD","LU1115378108.SGD","LU1861215975.USD","LU1854104046.USD","BK1163","BK4605","IE00BFMHRM44.USD","BK1589","ON","BK1500"],"gpt_icon":0},{"id":"2588019669","title":"中国生物制药(01177)：罗替高汀贴片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588019669","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588019669?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:37","pubTimestamp":1764751048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团开发的“罗替高汀贴片”已获得中国国家药品监督管理局的上市批准，用于早期特发性帕金森病症状及体征的单药治疗，或与左旋多巴联合用于病程中的各个阶段。罗替高汀贴片已被纳入《中国帕金森病治疗指南》等多部指南及共识，成为早发型帕金森病的初期治疗推荐用药。目前，集团管线内还有十余款贴剂产品有望于2030年前获批上市，进一步巩固集团在透皮贴剂领域的领导地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)：罗替高汀贴片获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","BK1589","01177","BK1521"],"gpt_icon":0},{"id":"2588023805","title":"每日卖空追踪 | 中国生物制药 12月03日卖空量成交279.6万股，卖空比例为6.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588023805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588023805?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:30","pubTimestamp":1764750618,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间12月03日，跌2.32%，卖空量成交279.6万股，较上一交易日减少39.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163252a7210d4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163252a7210d4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1521","BK1515","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1589","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588099335","title":"【券商聚焦】国信证券：港股短线的调整为2026年赢得空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2588099335","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588099335?lang=zh_cn&edition=full","pubTime":"2025-12-03 11:09","pubTimestamp":1764731351,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国信证券研报指，港股短线的调整为2026年赢得空间。但站在布局明年的角度，有不少乐观的理由，包括：1、美联储持续降息将带来流动性的逐步宽松；2、AI 的进步值得期待，26 年有望更加广泛的 AI 应用推出；3、汽车、半导体明年依然有较好的利润增长；4、外卖战有望在 26 年的某个时间趋缓；5、十五五规划落地带来的积极影响。美元指数将在26年初期持续走弱，这有利于新兴市场的估值修复。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970805","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0633140560.USD","LU1251922891.USD","02121","IE0008369823.USD","LU1961090484.USD","IE00B0169L03.USD","09999","LU0315179316.USD","LU0051755006.USD","LU2399975544.HKD","LU0588546209.SGD","LU2476274720.SGD","BK1583","IE0032834883.USD","01801","LU0320764599.SGD","06181","LU0456827905.SGD","LU0307460666.USD","IE00B97KM107.HKD","00325","LU0611395673.USD","HK0000306701.USD","LU0862451753.SGD","01318","01177","LU0052750758.USD","LU0469268626.HKD","LU0039217434.USD","LU1152091168.USD","HK0000320223.HKD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU1794554557.SGD","LU1226287875.USD","LU1303224171.USD","LU0871576103.HKD","BK1163","LU0106959298.USD","LU0049853897.USD","002736","LU1688375341.USD","BK1609","LU0501845795.SGD","LU1008478684.HKD","LU0348825331.USD","01093"],"gpt_icon":1},{"id":"2588062795","title":"中国生物制药12月02日主力净流出896.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062795","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588062795?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:15","pubTimestamp":1764663352,"startTime":"0","endTime":"0","summary":"12月02日, 中国生物制药股价跌0.14%，报收6.91元，成交金额2.2亿元，换手率0.17%，振幅1.30%，量比0.57。中国生物制药今日主力资金净流出896.7万元，上一交易日主力净流入1312.8万元。该股近5个交易日上涨0.43%，主力资金累计净流入5217.7万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1.8亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202162118a4c79727&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202162118a4c79727&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","01177","BK1589","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1521","BK1191"],"gpt_icon":0},{"id":"2588515701","title":"中国生物制药的11月：站在新十年全新起点，迈向全球创新药企行列","url":"https://stock-news.laohu8.com/highlight/detail?id=2588515701","media":"正大制药订阅号","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588515701?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:02","pubTimestamp":1764630130,"startTime":"0","endTime":"0","summary":"中国生物制药亮相Jefferies全球医疗健康大会当地时间11月18日，中国生物制药亮相2025年Jefferies全球医疗健康大会，董事会主席谢其润出席会议，海外业务负责人杨振昌发表演讲。作为中国创新药企的中坚力量，中国生物制药正站在新十年的全新起点，稳步迈向全球创新药企行列。至此，中国生物制药已成功创建国家级绿色工厂2家、省级绿色工厂3家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202072105a4c6967d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202072105a4c6967d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","IE00BZ08YR35.GBP","BK1521","IE00BZ08YT58.USD","01177","06978","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1161","BK1515","BK1589","BK1191"],"gpt_icon":0},{"id":"2588505726","title":"中国生物制药(01177)自主研发的国家1类创新药TRD208在中国开展的I期临床试验已顺利完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2588505726","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588505726?lang=zh_cn&edition=full","pubTime":"2025-12-01 18:17","pubTimestamp":1764584220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团自主研发的国家1类创新药TRD208在中国开展的I期临床试验已顺利完成首例患者入组。TRD208是一款全球首创的非阿片类多靶点多模式镇痛创新药，有望成为急性疼痛领域的重磅药物。临床前数据表明，TRD208在术后痛模型中表现出快速起效、强效镇痛、时间持久的优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","HK0000165453.HKD","BK1574","BK1161","BK1521","01177","BK1589","159992","IE00BZ08YR35.GBP","BK1191"],"gpt_icon":0},{"id":"2588684701","title":"友芝友生物 M701 II 期临床成果登国际顶刊 EHO 恶性腹水治疗获突破性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2588684701","media":"药研界面","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588684701?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:06","pubTimestamp":1764580014,"startTime":"0","endTime":"0","summary":"武汉友芝友生物制药股份有限公司宣布，核心管线产品 M701 治疗恶性腹水的 II 期临床研究结果，正式发表于国际知名学术期刊《Experimental Hematology & Oncology》，标志着该创新疗法的临床价值获国际学术界权威认可。同时，M701 组总生存期呈现明确延长趋势，6 个月生存率达 33.3%，远超对照组的 12.1%，且安全性良好，无新增严重不良反应，相关不良事件可控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201221912a4c5fbda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201221912a4c5fbda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","01177","BK1191","BK1589","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","BK1515","HK0000165453.HKD"],"gpt_icon":0},{"id":"2588701562","title":"每日卖空追踪 | 中国生物制药 12月01日卖空量成交510.6万股，卖空比例为7.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701562","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701562?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577819,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间12月01日，跌1.84%，卖空量成交510.6万股，较上一交易日减少42.71%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120116321697895481&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120116321697895481&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1521","BK1191"],"gpt_icon":0},{"id":"2588701680","title":"中国生物制药盘中异动 下午盘股价大跌3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701680?lang=zh_cn&edition=full","pubTime":"2025-12-01 13:35","pubTimestamp":1764567341,"startTime":"0","endTime":"0","summary":"2025年12月01日下午盘13时35分，中国生物制药股票出现波动，股价大幅下跌3.12%。截至发稿，该股报6.830港元/股，成交量3517.55万股，换手率0.19%，振幅3.83%。资金方面，该股资金流入9345.69万港元，流出1.28112亿港元。中国生物制药股票所在的药品行业中，整体跌幅为0.39%。其相关个股中，天大药业、康哲药业、白花油涨幅较大，振幅较大的相关个股有三爱健康集团、德琪医药-B、海王英特龙，振幅分别为12.50%、8.19%、7.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011335419789095e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512011335419789095e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","IE00BZ08YS42.EUR","01177","BK1521","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","BK1589"],"gpt_icon":0},{"id":"2586284363","title":"中国生物制药(01177.HK)涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586284363","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586284363?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:41","pubTimestamp":1764124893,"startTime":"0","endTime":"0","summary":"每经AI快讯，中国生物制药(01177.HK)涨近3%，截至发稿，涨2.87%，报7.16港元，成交额1.74亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511263575219756.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511263575219756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","HK0000165453.HKD","BK1589","IE00BZ08YS42.EUR","01177","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","BK1191"],"gpt_icon":0},{"id":"2586428185","title":"港股异动 | 中国生物制药(01177)涨超4% 旗下正大晴天自研HER2双抗ADC新辅助治疗乳腺癌取得重要突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2586428185","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586428185?lang=zh_cn&edition=full","pubTime":"2025-11-26 10:28","pubTimestamp":1764124108,"startTime":"0","endTime":"0","summary":"消息面上，11月25日，注射用TQB2102单药用于HER2阳性乳腺癌新辅助治疗的Ⅱ期临床研究结果，获国际著名期刊《临床肿瘤学杂志》 在线发表。TQB2102是中国生物制药旗下正大天晴自主研发的一种靶向HER2两个非重叠表位ECD2及ECD4的抗体偶联药物。该项研究由复旦大学附属肿瘤医院邵志敏教授团队领衔，为首个证实双表位HER2 ADC TQB2102在乳腺癌新辅助治疗阶段具有良好疗效和安全性的研究，Ⅲ期注册临床研究正在开展中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YR35.GBP","BK1521","IE00BZ08YT58.USD","ADC","01177","BK4080","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1515","BK1589","BK1191","BK4231"],"gpt_icon":0},{"id":"2586018298","title":"中国生物制药盘中异动 早盘股价大涨3.02%报7.170港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586018298","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586018298?lang=zh_cn&edition=full","pubTime":"2025-11-26 09:41","pubTimestamp":1764121304,"startTime":"0","endTime":"0","summary":"2025年11月26日早盘09时41分，中国生物制药股票出现异动，股价大幅上涨3.02%。截至发稿，该股报7.170港元/股，成交量449.613万股，换手率0.02%，振幅2.44%。资金方面，该股资金流入2098.5万港元，流出742.85万港元。中国生物制药股票所在的药品行业中，整体涨幅为0.73%。其相关个股中，三生制药、艾美疫苗、石药集团涨幅较大，振幅较大的相关个股有先声药业、九源基因、三生制药，振幅分别为6.47%、6.40%、5.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126094144977fa6c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126094144977fa6c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","IE00BZ08YT58.USD","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589","BK1515","01177","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2585050467","title":"上海重磅发布！医药产业又迎政策支持 机构看好创新药产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2585050467","media":"券商中国","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585050467?lang=zh_cn&edition=full","pubTime":"2025-11-24 20:55","pubTimestamp":1763988955,"startTime":"0","endTime":"0","summary":"医药产业，又迎来政策支持！值得关注的是，近日多家券商研究机构发布研报，表示看好创新医疗器械以及创新药产业链。上海重磅发布日前，上海市人民政府办公厅印发《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若干措施》。在国家医保药品和“新优药械”产品目录发布1个月内，根据临床需求和医院特色，及时配备使用。看好创新药产业链、创新医疗器械。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124205450a70e6201&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124205450a70e6201&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","02228","BK1588","BK1574","00013","06978","01548","01177","02268","03692","00867","BK1161","BK1191","02359","01877","BK1587"],"gpt_icon":0},{"id":"2586301449","title":"每日卖空追踪 | 中国生物制药 11月24日卖空量成交765万股，卖空比例为9.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586301449","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586301449?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973019,"startTime":"0","endTime":"0","summary":"中国生物制药北京时间11月24日，涨0.88%，卖空量成交765万股，较上一交易日减少69.78%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112416322795171a55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112416322795171a55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","HK0000165453.HKD","BK1191","BK1521","01177","IE00BZ08YR35.GBP","BK1589"],"gpt_icon":0},{"id":"2586544932","title":"中国生物制药11月24日主力净流入2423.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2586544932","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586544932?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:15","pubTimestamp":1763972128,"startTime":"0","endTime":"0","summary":"11月24日, 中国生物制药股价涨0.88%，报收6.86元，成交金额5.3亿元，换手率0.41%，振幅2.94%，量比1.41。中国生物制药今日主力资金净流入2423.3万元，上一交易日主力净流出546.7万元。该股近5个交易日下跌4.35%，主力资金累计净流入4214.7万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入3.2亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124161801951711d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124161801951711d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1521","BK1589","BK1191","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1515","IE00BZ08YT58.USD","01177"],"gpt_icon":0},{"id":"2585439567","title":"【券商聚焦】中国银河：看好2026年医药行业投资机会 近期震荡调整后估值已回落至相对低位","url":"https://stock-news.laohu8.com/highlight/detail?id=2585439567","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585439567?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:13","pubTimestamp":1763946817,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券发研报指，2026年政策展望：十五五开局之年，深化三医协同，系统性推进改革。总体上，2026年预计政策端仍将驱动医药行业腾笼换鸟、创新升级。该机构看好2026年医药行业投资机会，近期震荡调整后估值已回落至相对低位，有望在2026年重启升势，投资思路上寻找医药硬科技和细分赛道α，推荐关注创新药、创新器械、医疗AI方向，关注医药消费复苏及独立第三方ICL。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970148","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","LU0588546209.SGD","LU1303224171.USD","02359","BK1589","LU0039217434.USD","601881","LU3063872942.SGD","LU0052750758.USD","03692","LU1770034418.SGD","IE00B0JY6N72.USD","LU0516423091.SGD","01801","LU0051755006.USD","LU2097828631.EUR","BK1610","LU0456827905.SGD","LU2097828714.EUR","BK0188","BK1161","LU1794554557.SGD","LU0516422952.EUR","LU0359202008.SGD","LU0572944931.SGD","LU1720050803.USD","LU0348735423.USD","LU1880383366.USD","HK0000165453.HKD","LU2488822045.USD","LU0326950275.SGD","LU1046422090.SGD","06160","02269","LU0320764599.SGD","BK1500","LU0359201885.HKD","06990","LU2543165471.USD","LU1023057109.AUD","LU0516422440.USD","01177","LU1242518857.USD","06881","LU2045819591.USD","01276","LU1969619763.USD","LU0348825331.USD","LU1242518931.SGD","LU0823426308.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.031},{"period":"1month","weight":-0.0129},{"period":"3month","weight":-0.2278},{"period":"6month","weight":0.533},{"period":"1year","weight":1.1008},{"period":"ytd","weight":1.18}],"compareEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":-0.0006},{"period":"3month","weight":0.0204},{"period":"6month","weight":0.0901},{"period":"1year","weight":0.3137},{"period":"ytd","weight":0.2929}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.409091,"avgChangeRate":0.005246},{"month":2,"riseRate":0.681818,"avgChangeRate":0.063302},{"month":3,"riseRate":0.590909,"avgChangeRate":0.048254},{"month":4,"riseRate":0.5,"avgChangeRate":0.025891},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.007237}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SINO BIOPHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}